+ Watch ATRS
on My Watchlist
The Company develops, produces and markets pharmaceutical delivery products, including transdermal gels, oral fast melting tablets and reusable needle-free and disposable mini-needle injector systems.
Antares is gearing up for what I think will be a block bluster of a drug and that is Vibex MTX. Management has already said they plan to file an NDA with the FDA in Q1 of 2013 and when they do the stock should take off in anticipation of an early release from the FDA. Management has already done their own private studies with MTX and had an astonishing 96% approval rating. At a little under $4 a share, I think this could really benefit someones portfolio for the next two to three years.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions